Targeting the hypnozoite reservoir of Plasmodium vivax : the hidden obstacle to malaria elimination

Plasmodium vivax is the major species of malaria parasite outside Africa. It is especially problematic in that the infection can relapse in the absence of mosquitoes by activation of dormant hypnozoites in the liver. Medicines that target the erythrocytic stages of Plasmodium falciparum are also act...

Full description

Saved in:
Bibliographic Details
Published in:Trends in parasitology 2010-03, Vol.26 (3), p.145-151
Main Authors: Wells, Timothy N.C, Burrows, Jeremy N, Baird, J. Kevin
Format: Article
Language:English
Subjects:
Animals
Antimalarials - therapeutic use
Biological and medical sciences
Disease Reservoirs
Gastroenterology and Hepatology
Human protozoal diseases
Humans
Infectious Disease
Infectious diseases
Life Cycle Stages
Liver - parasitology
Malaria
Malaria - drug therapy
Malaria - epidemiology
Malaria - parasitology
Medical sciences
Parasitic diseases
Plasmodium falciparum
Plasmodium vivax
Protozoal diseases
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Plasmodium vivax is the major species of malaria parasite outside Africa. It is especially problematic in that the infection can relapse in the absence of mosquitoes by activation of dormant hypnozoites in the liver. Medicines that target the erythrocytic stages of Plasmodium falciparum are also active against P. vivax , except where these have been compromised by resistance. However, the only clinical therapy against relapse of vivax malaria is the 8-aminoquinoline, primaquine. This molecule has the drawback of causing haemolysis in genetically sensitive patients and requires 14 days of treatment. New, safer and more-easily administered drugs are urgently needed, and this is a crucial gap in the broader malaria-elimination agenda. New developments in cell biology are starting to open ways to the next generation of drugs against hypnozoites. This search is urgent, given the time needed to develop a new medication.
ISSN:1471-4922
1471-5007
DOI:10.1016/j.pt.2009.12.005